



pBluescript II XR Predigested Vector

Instruction Manual

Catalog #212240

Revision C.0

For Research Use Only. Not for use in diagnostic procedures.

212240-12



Agilent Technologies

LIMITED PRODUCT WARRANTY

This warranty limits our liability to replacement of this product. No other warranties of any kind, express or implied, including without limitation, implied warranties of merchantability or fitness for a particular purpose, are provided by Agilent. Agilent shall have no liability for any direct, indirect, consequential, or incidental damages arising out of the use, the results of use, or the inability to use this product.

ORDERING INFORMATION AND TECHNICAL SERVICES

Email

techservices@agilent.com

World Wide Web

www.genomics.agilent.com

Telephone

Location	Telephone
United States and Canada	800 227 9770
Austria	01 25125 6800
Benelux	02 404 92 22
Denmark	45 70 13 00 30
Finland	010 802 220
France	0810 446 446
Germany	0800 603 1000
Italy	800 012575
Netherlands	020 547 2600
Spain	901 11 68 90
Sweden	08 506 4 8960
Switzerland	0848 8035 60
UK/Ireland	0845 712 5292
All Other Countries	Please visit www.genomics.agilent.com and click Contact Us

pBluescript II XR Predigested Vector

CONTENTS

Materials Provided	1
Storage Conditions	1
Additional Materials Required	1
Introduction	2
pBluescript II SK (+) Phagemid	3
Cloning Protocol for pBluescript II XR Predigested Vector	4
Cloning Considerations	4
Ligating the Insert	4
Transformation	5
Verifying the Presence of the Insert	5
Preparation of Media and Reagents	5
References	6
Endnotes	6
MSDS Information	6

pBluescript II XR Predigested Vector

MATERIALS PROVIDED

Materials provided	Concentration	Quantity
pBluescript II XR predigested vector ^{a,b}	20 ng/μl	55 μl (1100 ng)
Test insert (kanamycin-resistance gene; 1.4 kb)	10 ng/μl	3 μl (30 ng)

^a The pBluescript II XR predigested vector is digested with *EcoR* I and *Xho* I, and CIAP-treated.

^b The pBluescript II XR predigested vector is derived from pBluescript II SK (+).

STORAGE CONDITIONS

All components: -20°C

ADDITIONAL MATERIALS REQUIRED

High efficiency competent cells ($\geq 5 \times 10^9$ cfu/μg DNA for preparing libraries)

LB-ampicillin agar plates[§]

LB-kanamycin agar plates[§]

Isopropyl-β-D-thio-galactopyranoside (IPTG)

5-bromo-4-chloro-3-indoyl-β-D-galactopyranoside (X-gal)

[§] See *Preparation of Media and Reagents*.

Revision C.0

© Agilent Technologies, Inc. 2015.

INTRODUCTION


The pBluescript II XR predigested vector is a high-copy-number pUC-based plasmid with ampicillin resistance and the convenience of blue-white color screening. The vector supplied is predigested with *EcoR* I and *Xho* I restriction enzymes and is CIAP-treated to reduce the background of nonrecombinants. The multiple cloning site (MCS) contains unique restriction enzyme recognition sites organized with alternating 5'- and 3'-overhangs to allow serial exonuclease III/mung bean nuclease deletions. T3 and T7 RNA polymerase promoters flank the polylinkers for *in vitro* RNA synthesis. The choice of promoter used to initiate transcription determines which strand of the DNA insert will be transcribed. *BssH* II sites flank the T3 and T7 promoters. This rare six-base restriction enzyme allows the insert plus the RNA promoters to be excised and used for gene mapping.

Expression in the pBluescript II XR vector is driven by the *lac* promoter, which is repressed in the presence of the LacI protein and is inducible by isopropyl- β -D-thio-galactopyranoside (IPTG). In bacteria expressing the *lacZ* Δ M15 mutation and *lacI*, such as Agilent's XL10-Gold cells, colonies containing vector without insert will be blue in the presence of 5-bromo-4-chloro-3-indoyl- β -D-galactopyranoside (X-gal) and IPTG. Ampicillin-resistant colonies containing vector with insert will be white and can express the inserted gene as a fusion protein. The MCS and T7 and T3 RNA polymerase promoter sequences are present in the N-terminal portion of a *lacZ* gene fragment. There are 36 amino acids of the *lacZ* protein from the methionine (Met) sequence to the *EcoR* I site. There are a total of 131 amino acids of the *lacZ* protein present, but this coding sequence is interrupted by the large MCS.


The pBluescript II SK (+) vector can be rescued as single-stranded DNA (ss-DNA). pBluescript II phagemids contain a 454-bp filamentous f1 phage intergenic region (M13 related), which includes the 307-bp origin of replication. The (+) orientation of the f1 intergenic region allows the rescue of *lacZ* sense ss-DNA by a helper phage. This ss-DNA can be used for dideoxynucleotide sequencing (Sanger method) or site-directed mutagenesis.

Additional sequence and restriction site information for the pBluescript II SK (+) vector is available from the Agilent website (<http://www.genomics.agilent.com>).

pBluescript II SK (+) Phagemid



pBluescript II SK (+) Multiple Cloning Site Region (sequence shown 598–826)



Feature	Nucleotide Position
f1 (+) origin of ss-DNA replication	135–441
β -galactosidase α -fragment coding sequence (<i>lacZ'</i>)	460–816
multiple cloning site	653–760
T7 promoter transcription initiation site	643
T3 promoter transcription initiation site	774
<i>lac</i> promoter	817–938
pUC origin of replication	1158–1825
ampicillin resistance (<i>bla</i>) ORF	1976–2833

FIGURE 1 The pBluescript II SK (+) phagemid vector. The complete sequence and list of restriction sites are available at www.genomics.agilent.com. The vector sequence is also available from the GenBank® database (accession #X52328). The vector supplied in this kit is predigested with *EcoR* I and *Xho* I restriction enzymes, and does not contain the sequence between *EcoR* I and *Xho* I.

CLONING PROTOCOL FOR pBLUESCRIPT II XR PREDIGESTED VECTOR

The pBluescript II XR vector is designed for the convenient insertion of DNA inserts compatible with the *EcoR I/Xho I* cloning site. This vector features an MCS with twelve unique, conveniently arranged restriction sites for removing the DNA sequence of interest.

Cloning Considerations

The DNA fragment to be inserted should have ends compatible with the *EcoR I* and *Xho I* ends of the predigested pBluescript II XR vector.

The insert DNA should be suspended in a volume of TE buffer[§] that will allow the concentration of the insert DNA to be the same as the concentration of the vector DNA (0.02 µg/µl).

Ligating the Insert

For ligation, the ideal insert-to-vector molar ratio of DNA is variable; however, a reasonable starting point is a 1:1 insert-to-vector ratio. The ratio is calculated using the following equation:

$$X \text{ µg of insert} = \frac{(\text{Number of base pairs of insert}) (0.02 \text{ µg of pBluescript vector})}{2961 \text{ bp of pBluescript vector}}$$

where *X* is the quantity of insert (in micrograms) required for a 1:1 insert-to-vector molar ratio. Multiply *X* by 2 to get the quantity of insert required for a 2:1 ratio, multiply *X* by 3 to get the quantity of insert required for a 3:1 ratio, etc.

1. Prepare one control and two experimental 5-µl ligation reactions by adding the following components to separate sterile 1.5-ml microcentrifuge tubes:

Ligation reaction components	Control	Experimental	
	1 ^a	2 ^b	3 ^b
Prepared pBluescript II XR vector (0.02 µg/µl)	1.0 µl	1.0 µl	1.0 µl
Prepared insert (0.02 µg/µl)	0 µl	X µl	X µl
Test insert (0.01 µg/µl)	1.0 µl	0 µl	0 µl
rATP [10 mM (pH 7.0)]	0.5 µl	0.5 µl	0.5 µl
Ligase buffer (10×) [§]	0.5 µl	0.5 µl	0.5 µl
T4 DNA ligase (4 U/µl)	0.5 µl	0.5 µl	0.5 µl
Double-distilled water (ddH ₂ O) to 5 µl	1.5 µl	Y µl	Y µl

^a This control verifies the ability of the vector to ligate the test insert.

^b These experimental ligation reactions vary the insert-to-vector ratio. Expect a majority of the transformant colonies to represent recombinants.

2. Incubate the reactions overnight at 4°C.

[§] See *Preparation of Media and Reagents*

Transformation

1. Transform competent bacterial cells with 1–5 μl of the ligation reactions. See reference 1 for a transformation protocol.

Note *We recommend using competent cells with transformation efficiencies $\geq 5 \times 10^9$ cfu/ μg for preparing libraries.*

2. Plate the control-transformed cells on LB-kanamycin agar plates and the experimental-transformed cells on LB-ampicillin agar plates.
3. Incubate at 37°C overnight.
4. Pick 50 colonies, transfer them to an LB-ampicillin agar plate containing X-gal and IPTG, and incubate the plates at 37°C. White colonies contain the test insert.

Verifying the Presence of the Insert

Individual colonies can be examined to identify the plasmids with inserts and the insert size directly by PCR or by restriction analysis. The T3 and the T7 primers are recommended for PCR amplification and sequencing.

PREPARATION OF MEDIA AND REAGENTS

<p>LB Agar (per Liter) 10 g of NaCl 10 g of tryptone 5 g of yeast extract 20 g of agar Add deionized H₂O to a final volume of 1 liter Adjust pH to 7.0 with 5 N NaOH Autoclave Pour into petri dishes (~25 ml/100-mm plate)</p>	<p>LB–Ampicillin Agar (per Liter) 1 liter of LB agar, autoclaved Cool to 55°C Add 10 ml of 10-mg/ml filter-sterilized ampicillin Pour into petri dishes (~25 ml/100-mm plate)</p>
<p>LB-Kanamycin Agar (per Liter) Prepare 1 liter of LB agar Autoclave Cool to 55°C Add 50 mg of filter-sterilized kanamycin Pour into petri dishes (~25 ml/100-mm plate)</p>	<p>Ligase Buffer (10×) 500 mM Tris HCl (pH 7.5) 70 mM MgCl₂ 10 mM dithiothreitol (DTT)</p> <p>Note <i>rATP is added separately in the ligation reaction</i></p>
<p>TE Buffer 10 mM Tris-HCl (pH 7.5) 1 mM EDTA</p>	

REFERENCES

1. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., *et al.* (1987). *Current Protocols in Molecular Biology*. John Wiley & Sons, New York.

ENDNOTES

GenBank® is a registered trademark of National Institutes of Health.

MSDS INFORMATION

Material Safety Data Sheets (MSDSs) are provided online at <http://www.genomics.agilent.com>. MSDS documents are not included with product shipments.